BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Methylene Tetrahydrofolate Reductase C677T Mutation and Left Ventricular Hypertrophy in Turkish Patients with Type II Diabetes Mellitus

  • Yilmaz, Hulya (Institute of Experimental Medical Research, Department of Molecular Medicine, Istanbul University) ;
  • Agachan, Bedia (Institute of Experimental Medical Research, Department of Molecular Medicine, Istanbul University) ;
  • Ergen, Arzu (Institute of Experimental Medical Research, Department of Molecular Medicine, Istanbul University) ;
  • Karaalib, Zeynep Ermis (Taksim State Hospital, Department of Internal Medicine) ;
  • Isbir, Turgay (Institute of Experimental Medical Research, Department of Molecular Medicine, Istanbul University)
  • Published : 2004.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

This study was designed to investigate, in the Turkish population, the association of methylene tetrahydrofolate reductase (MTHFR) C677T polymorphism and left ventricular hypertrophy (LVH) in patients with type II diabetes mellitus. Our study included 249 patients with type II diabetes mellitus (102 men, 147 women) and 214 healthy volunteers as controls (91 men, 123 women). MTHFR C677T genotypes were determined by polymerase chain reaction, restriction fragment length polymorphism techniques. No differences were observed in the distribution of MTHFR genotypes or allele frequencies in the cases versus the controls. The frequency of the MTHFR-mutated allele (T) was 31.7% in the type II diabetes mellitus versus 31.1% of the controls. The homozygous mutation (T/T) in the MTHFR gene was identified in 12% of the type II diabetes mellitus versus 9.3% of the controls. Patients with the TT genotype showed a higher prevalence of LVH when compared to patients with the CC and CT genotypes (p = 0.01). The MTHFR gene C677T mutation may be a possible risk factor for the development of LVH in the type II diabetic patients.

Keywords

References

  1. Abdella, N., Mojiminiyi, O. A. and Akanji, A. O. (2000) Homocysteine and endogenous markers of renal function in type 2 diabetic patients without coronary heart disease. Diabetes Res. Clin. Pract. 50, 177-185.
  2. Agullo-Ortuno, M. T., Albaladejo, M. D., Parra, S., Rodriguez-Manotas, M., Fenollar, M., Ruiz-Espejo, F., Tebar, J. and Martinez, P. (2002) Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin. Chim. Acta 326, 105-112. https://doi.org/10.1016/S0009-8981(02)00287-5
  3. Ambrosch, A., Dierkes, J., Lobmann, R., Kuhne, W., Konig, W., Luley, C. and Lehnert, H. (2001) Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabet. Med. 18, 185-192. https://doi.org/10.1046/j.1464-5491.2001.00445.x
  4. Audelin, M. C. and Genest, J. Jr. (2001) Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 159, 497-511. https://doi.org/10.1016/S0021-9150(01)00531-7
  5. Bostom, A. G., Shemin, D., Lapane, K. L., Miller, J. W., Sutherland, P., Nadeau, M., Seyoum, E., Hartman, W., Prior, R., Wilson, P. W. F. and Selhub, J. (1995) Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 114, 93-103. https://doi.org/10.1016/0021-9150(94)05470-4
  6. Chico, A., Perez, A., Cordoba, A., Arcelus, R., Carreras, G., de Leiva, A., Gonzalez-Sastre, F. and Blanco-Vaca, F. (1998) Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 41, 684- 693. https://doi.org/10.1007/s001250050969
  7. De Luis, D. A., Fernandez, N., Arranz, M., Aller, R. and Izaola, O. (2002) Total homocysteine and cognitive deterioration in people with type 2 diabetes. Diabetes Res. Clin. Pract. 55, 185-190. https://doi.org/10.1016/S0168-8227(01)00300-X
  8. Frosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A., Matthews, R. G., Boers, G. J., den Heijer, M., Kluijtmans, L. A. and van den Heuvel, L. P., et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 10, 111-113. https://doi.org/10.1038/ng0595-111
  9. Fujita, H., Nari, T., Meguro, H., Ishii, T., Hanyu, O., Suzuki, K., Kamoi, K. and Ito, S. (1999) No association between MTHFR gene polymorphism and diabetic nephropathy in Japanese type II diabetic patients with proliferative diabetic retinopathy. J. Diabetes Complications 13, 284-287. https://doi.org/10.1016/S1056-8727(99)00057-4
  10. Grundy, S. M., Benjamin, U., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C. and Sowers, J. R. (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100, 1134-1146. https://doi.org/10.1161/01.CIR.100.10.1134
  11. Haraki, T., Takegoshi, T., Kitoh, C., Kajinami, K., Wakasugi, T., Hirai, J., Shimada, T., Kawashiri, M., Inazu, A., Koizumi, J. and Mabuchi, H. (2001) Hyperhomocysteinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease. Clin. Nephrol. 56, 132-139.
  12. Herrmann, W., Quast, S., Ullrich, H., Schultze, H., Bodis, M. and Geisel, J. (1999) Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. Atherosclerosis 144, 91-101.
  13. Hoogeveen, E. K., Kostense, P. J., Beks, P. J., Mackaay, A. J., Jakobs, C., Bouter, L. M., Heine, R. J. and Stehouwer, C. D. (1998) Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulindependent diabetes mellitus: a population-based study. Arterioscler Thromb. Vasc. Biol. 18, 133-138. https://doi.org/10.1161/01.ATV.18.1.133
  14. Hultberg, B., Agardh, E., Andersson, A., Brattstrom, L., Isakson, A., Israelsson, B. and Agardh, C. D. (1991) Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand. J. Clin. Lab. Invest. 51, 277-282. https://doi.org/10.3109/00365519109091615
  15. Kang, S. S. and Wong, P. W. (1996) Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Atherosclerosis 119, 135-138. https://doi.org/10.1016/0021-9150(95)05648-3
  16. Kirkendall, W. M., Feianleib, M., Freis, E. D. and Mark, A. L. (1980) Recommendation for human blood pressure determination by sphygomomanometers. Circulation 62, 1146-1155.
  17. Ma, J., Stampfer, M. J., Hennekens, C. H., Frosst, P., Selhub, J., Horsford, J., Malinow, M. R., Willett, W. C. and Rozen, R. (1996) Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 94, 2410-2416. https://doi.org/10.1161/01.CIR.94.10.2410
  18. Mager, A., Battler, A., Birnbaum, Y., Magal, N. and Shohat, M. (2002) Plasma homocysteine, methylenetetrahydrofolate reductase genotypes, and age at onset of symptoms of myocardial ischemia. Am. J. Cardiol. 89, 919-923. https://doi.org/10.1016/S0002-9149(02)02239-7
  19. Miller, S. A., Dykes, D. D. and Polesky, H. F. (1988) A simples salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215. https://doi.org/10.1093/nar/16.3.1215
  20. Neugebauer, S., Baba, T. and Watanabe, T. (1998) Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 352, 454.
  21. Noiri, E., Taguchi, J., Nakao, A. and Fujita, T. (2000) MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care 23, 260.
  22. Passaro, A., Vanini, A., Calzoni, F., Alberti, L., Zamboni, P. F., Fellin, R. and Solini, A. (2001) Plasma homocysteine, methylenetetrahydrofolate reductase mutation and carotid damage in elderly healthy women. Atherosclerosis 157, 175-180. https://doi.org/10.1016/S0021-9150(00)00696-1
  23. Ravera, M., Viazzi, F., Berruti, V., Leoncini, G., Zagami, P., Bezante, G. P., Rosatto, N., Ravazzolo, R., Pontremoli, R. and Deferrari, G. (2001) 5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. Am. J. Hypertension 14, 371-376. https://doi.org/10.1016/S0895-7061(00)01296-6
  24. Report of a WHO Consultation: Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications, Geneva, 1999.
  25. Robillon, J. F., Canivet, B., Candito, M., Sadoul, J. L., Jullien, D., Morand, P., Chambon, P. and Freychet, P. (1994) Type 1 diabetes mellitus and homocyst(e)ine. Diabetes Metab. 20, 494-496.
  26. Rees, M. M. and Rodgers, G. M. (1993) Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb. Res. 71, 337-359. https://doi.org/10.1016/0049-3848(93)90160-P
  27. Shcherbak, N. S., Shutskaya, Z. V., Sheidina, A. M., Larionova, V. I. and Schwartz, E. I. (1999) Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Mol. Genet. Metab. 68, 375-378. https://doi.org/10.1006/mgme.1999.2909
  28. Shpichinetsky, V., Raz, I., Friedlander, Y., Goldschmidt, N., Wexler, I. D., Ben-Yehuda, A. and Friedman, G. (2000) The association between two common mutations, C677T and A1298C, in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J. Nutr. 130, 2493-2497.
  29. Smyth, J. S., Savage, D. A. and Maxwell, A. P. (1999) MTHFR gene polymorphism and diabetic nephropathy in type 1 diabetes. Lancet 353, 1156-1157. https://doi.org/10.1016/S0140-6736(98)05792-4
  30. Spence, J. D., Malinow, M. R., Barnett, P. A., Marian, A. J., Freeman, D. and Hegele, R. A. (1999) Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. Stroke 30, 969-973. https://doi.org/10.1161/01.STR.30.5.969
  31. Spence, M. S., McGlinchey, P. G., Patterson, C. C., Belton, C., Murphy, G., McMaster, D., Forgarty, D. G., Evans, A. E. and McKoown, P. P. (2002) Family-based investigation of the C677T polymorphism of the methylenetetrahydrofolate reductase gene in ischaemic heart disease. Atherosclerosis 165, 293-299. https://doi.org/10.1016/S0021-9150(02)00239-3
  32. Ueland, P. M., Hustad, S., Schneede, J., Refsum, H. and Vollset, S. E. (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol. Sci. 22, 195-201. https://doi.org/10.1016/S0165-6147(00)01675-8
  33. Wilson, P. W., D'Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H. and Kannel, W. B. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847. https://doi.org/10.1161/01.CIR.97.18.1837
  34. Yoo, J. H. and Park, S. C. (2000) Low plasma folate in combination with the 677 C$\rightarrow$T methylenetetrahydrofolate reductase polymorphism is associated with increased risk of coronary artery disease in Koreans. Thromb. Res. 97, 77-84. https://doi.org/10.1016/S0049-3848(99)00127-9
  35. Zhang, G. and Dai, C. (2001) Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular disease. Thromb. Res. 104, 187-195. https://doi.org/10.1016/S0049-3848(01)00352-8

Cited by

  1. MTHFR (Ala 222 Val) polymorphism and AMI in patients with type II diabetes mellitus vol.24, pp.2, 2009, https://doi.org/10.1007/s12291-009-0025-y
  2. Methylenetetrahydrofolate reductase C677T mutation in patients with alopecia areata in Turkish population vol.530, pp.1, 2013, https://doi.org/10.1016/j.gene.2013.08.016
  3. Association of homocysteine with type 2 diabetes: a meta-analysis implementing Mendelian randomization approach vol.14, pp.1, 2013, https://doi.org/10.1186/1471-2164-14-867
  4. Additive Interaction of MTHFR C677T and MTRR A66G Polymorphisms with Being Overweight/Obesity on the Risk of Type 2 Diabetes vol.13, pp.12, 2016, https://doi.org/10.3390/ijerph13121243
  5. Methylenetetrahydrofolate Reductase C677T Mutation and Nonalcoholic Fatty Liver Disease vol.52, pp.5, 2007, https://doi.org/10.1007/s10620-006-9565-7
  6. ACE I/D and MTHFR C677T polymorphisms are significantly associated with type 2 diabetes in Arab ethnicity: A meta-analysis vol.520, pp.2, 2013, https://doi.org/10.1016/j.gene.2013.02.017
  7. Association of pre-eclampsia with hyperhomocysteinaemia and methylenetetrahydrofolate reductase gene C677T polymorphism in a Turkish population vol.44, pp.5, 2004, https://doi.org/10.1111/j.1479-828X.2004.00283.x
  8. Association of MTHFR and PPARγ2 gene polymorphisms in relation to type 2 diabetes mellitus cases among north Indian population vol.511, pp.2, 2012, https://doi.org/10.1016/j.gene.2012.09.072
  9. Association between polymorphism of MTHFR c.677C>T and risk of cardiovascular disease in Turkish population: a meta-analysis for 2.780 cases and 3.022 controls vol.41, pp.1, 2014, https://doi.org/10.1007/s11033-013-2873-z
  10. Methylenetetrahydrofolate reductase C677T polymorphism in patients with Henoch-Schönlein purpura vol.53, pp.3, 2011, https://doi.org/10.1111/j.1442-200X.2010.03247.x
  11. Modulator Effects of the Methylenetetrahydrofolate Reductase C677T Polymorphism on Response to Vitamin B12 Therapy and Homocysteine Metabolism vol.31, pp.5, 2012, https://doi.org/10.1089/dna.2011.1422
  12. C677T mutation of methylenetetrahydrofolate reductase gene and serum homocysteine levels in Turkish patients with coronary artery disease vol.24, pp.1, 2006, https://doi.org/10.1002/cbf.1206
  13. Iperomocisteinemia e rischio cardiovascolare nel diabete: fantasia o realtà? vol.8, pp.1, 2007, https://doi.org/10.1007/BF03344557